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We therefore sought to clarify the role of TERT alterations in medulloblastoma, by assessing the frequency of TERT promoter hot-spot mutations [1, 6, 7, 9] , aberrant methylation of the critical cg11625005 TERT promoter CpG residue [3] , and TERT expression, in our tumour series. We show a common, subgroup-specific, involvement of TERT mutations in MB sHH alongside a wider involvement of TERT methylation across the MB subgroups, both associated with elevated TERT expression. Notably, in the non-infant MB sHH patient group aged 4 and over at diagnosis within our cohort, we show these genetic and epigenetic aberrations occur in both childhood and adult tumours, and in a mutually exclusive fashion, representing a defining molecular alteration in >75 % of this patient group.
TERT promoter mutations occurred at high frequency in both childhood [14/41 (34 %)] and adult [8/11 (73 %) ] MB sHH (Fig. 1b) in our cohort, more common than any coding mutation reported in these groups to date [TP53 30 %, PTCH1 27 %, DDX3X 18 %, all other genes <6 % (n = 33, data from cancer.sanger.ac.uk)]. The age distributions of mutated (4.7-15.5 years) and non-mutated (5.2-15.4 years) childhood patients did not differ significantly (p = 0.27; Mann-Whitney U test). TERT mutations were tumourspecific where germline DNA was available for comparison (n = 4) and exclusive to non-infant MB sHH in our investigations. Mutations were not found in MB WNT (n = 16; age range, 4.7-16.8 years), MB Group3 (n = 16; 1.5-16.1 years) or MB Group4 (n = 20; 2.4-15.8 years) from infants and children, or in tumours from infant MB sHH (<4.0 at diagnosis; n = 17; 0.2-3.5 years), consistent with the rarity of mutations in these subgroups reported by remke et al. [9] .
Aberrant TERT promoter methylation at cg11625005 was a feature of all medulloblastoma molecular subgroups, The childhood brain tumour medulloblastoma comprises four molecular disease subgroups (MB WNT , MB sHH , MB Group3 and MB Group4 ). However, large-scale wholeexome sequencing investigations have not identified defining genetic lesions for the non-MB WNT subgroups [8, 11] . recent studies reported in this journal and others [1, 3, 6, 7, 9] have identified frequent TERT promoter mutations and aberrant DNA methylation in CNs malignancies, suggesting an important mechanism in tumour development (Fig. 1a) . In medulloblastoma, Castelo-Branco et al. [3] reported a high frequency of TERT promoter methylation; while Killela et al. [6] described TERT promoter mutations, which Koelsche et al. [7] and remke et al. [9] subsequently reported, were most frequent in adult MB sHH , but rarer in childhood tumours. However, while TERT mutations have been associated with elevated expression in other cancers [1, 5] , and account for a proportion of MB sHH , the relative contribution of TERT methylation alterations has not yet been investigated alongside mutational analysis. Moreover, relationships between TERT promoter methylation and gene expression are unclear; the positive association reported across multiple malignancies by Castelo-Branco b Numbers and frequencies (%) of TERT mutations in medulloblastoma subgroups (subgroups determined as previously described [4, 10] ). Mutations were frequently and exclusively detected in the non-infant MB sHH subgroups (χ 2 test between MB sHH age groups shown). The three different mutations are colour coded (pink, purple and gold). c TERT promoter CpG site cg11625005 DNA methylation levels (β-value, assessed by Illumina Human Methylation 450 K array [2] ), are shown for normal cerebella (grey), MB sHH (by age; red), MB WNT (blue), MB Group3 (yellow), and MB Group4 (green). Black horizontal line, upper 99 % confidence interval of mean cerebellar methylation levels, above which tumours were classed as aberrantly hypermethylated. 'p' value, one-way analysis of variance between tumour groups shown. d TERT promoter methylation in MB sHH tumours from patients ≥4 years old at diagnosis. CpG site cg11625005 DNA methylation levels (β-value) are shown for TERT mutated (n = 10) and wild-type non-infant MB sHH (n = 17) and normal cerebella (n = 17, grey). specific mutations are colour coded as above (b). The mean methylation level was significantly higher in wild-type tumours compared to either mutated tumours (p = 0.0006) or the normal cerebellum (p = 0.00001) (student's t test). Black horizontal line, see above (c). e TERT expression (by rNA-seq; further details given in supplementary Table 1 ) vs. TERT promoter CpG site cg11625005 DNA methylation levels and mutation status in 51 medulloblastomas. subgroup assignment is coloured as above (c). Mutated tumours, bold outlined boxes; wild-type tumours, circles. Dashed line, linear regression of methylation vs. expression in TERT wild-type tumours with associated 'p' values (pearson's correlation). VsD, variance-stabilised transform of normalised read counts aligned to eNsG00000164362. All tumour-specific data are summarised in supplementary Table 1 but varied significantly in level and incidence between tumour groups (p = 9 × 10 −6 , ANOVA); aberrant hypermethylation (with respect to normal cerebellar levels; n = 17, foetal to 67 years) was observed in 63 % (10/16) MB WNT , 69 % (11/16) MB Group3 and in 10 % (2/20) MB Group4 , while MB sHH tumours (36 %; 16/44 hypermethylated) showed greatest variation (Fig. 1c) . Notably, TERT hypermethylation showed significant age-dependent associations within the MB sHH group (0 % (0/6) >16 years; 52 % (11/21) 4-16 years; 29 % (5/17) <4 years; p = 0.05, χ 2 test). Moreover, TERT promoter mutation and aberrant methylation at cg11625005 were mutually exclusive in non-infant MB sHH within our cohort (Fig. 1d) suggesting methylation alterations contribute significantly to TERT alteration in this group, and possible common mechanistic effects. Aberrant hypermethylation was detected in 11/17 non-mutated vs. 0/10 mutated non-infant MB sHH tumours assessed [p = 0.001; Fisher's exact test (Fig. 1d)] .
To assess the potential mechanistic contributions of promoter mutation and methylation to TERT gene expression, we next assessed their association within our cohort using expression data generated by rNA-seq. TERT methylation and expression showed a significant positive and linear relationship (p = 0.001; pearson's correlation test) in TERT wild-type tumours across all medulloblastoma subgroups, while all TERT mutant tumours [all MB sHH ≥4 years (Fig. 1b) ] displayed high TERT expression in the absence of hypermethylation (Fig. 1e) .
Non-coding TERT promoter alterations, encompassing mutually exclusive mutation and aberrant hypermethylation, both associated with elevated TERT expression, are therefore a defining feature for the majority (>75 %) of non-infant MB sHH in our cohort, indicating a key mechanism in their molecular pathogenesis. Moreover TERT hypermethylation and deregulation, in the absence of mutation, suggest a wider involvement across the other medulloblastoma molecular subtypes, notably frequent in MB WNT and MB Group3 , but less so in MB Group4 , which now mandates further investigation.
Finally, our findings raise the potential importance of additional non-coding and/or epigenetic regulatory alterations in medulloblastoma, which have hitherto been overlooked by exome sequencing studies [8] . Despite current nomenclature, MB sHH is not solely defined by sHH pathway activation and sHH is likely to contribute alongside other frequently disrupted pathways, with TERT alterations representing the most common identified to date. We believe these findings have important implications for future diagnosis, research and targeted therapy of a significant proportion of medulloblastoma patients.
